Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Drugs prices are rising, but not as fast as you may think

An article by Forbes discusses healthcare costs, drug prices, government interventions and policy reform.

Largest health system in N.C. hit with antitrust lawsuit

Carolinas HealthCare System (CHS) is being accused of illegally keeping patients from lower-priced competitors by including steering restrictions in its contracts with insurers.

HHS funding bill advances to full Senate

For the second straight year, the appropriations bill covering HHS and its related agencies has been passed out of a Senate committee.

HHS emphasizes ACA success stories at forum

The heads of HHS and CMS tried to project confidence to insurers about the Affordable Care Act’s health insurance marketplaces after some of the largest companies announced plans to scale back their exchange offerings or proposed premium increases for 2017.

Senate setting up Zika conference

The Senate will be voting on an agreement to begin talks with the House on a long-disputed Zika funding package, reports the Hill.

House advances bills on health crisis readiness, sports medicine liability

Two pieces of legislation dealing with public health issues were passed out of the House Energy and Commerce Health Subcommittee June 8.

Med school injects health policy into curriculum

George Washington University’s School of Medicine and Health Sciences is integrating the usual clinical medical school studies with the policy issues affecting care and the healthcare system.

Feds crack down on Medicare ambulance fraud

Teams of federal officials have been fighting ambulance fraud where one fraudulent ambulance operator would shut down only to have another, sometimes headed by a friend or family member, replace it, reports JEMS.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup